Table 7.
Summary of the sensitivity analysis
| Parameter | Hydrocele average estimate | Lymphedema average estimate | Sources |
|---|---|---|---|
| Disease Progression & Incidence Rates | |||
| Percentage of clinical patients who experience ADL episodes per year | 70 % (45–90 %) | 95 % (90–95 %) | [8, 10–17] |
| Frequency of ADL episodes for clinical patients (in absence of MDA) | 2 (0–7) per year | 4 (0–7) per year | [8, 10–17] |
| Average duration of an ADL episode | 4 (1–9) days | 4 (1–9) days | [8, 10–17] |
| Disability weight for symptomatic LF infection | 0.11 (0.073–0.157) | 0.11 (0.073–0.157) | [40] |
| Mean age of the benefit cohorts (years) | Cohort 1: 20 (30) | Cohort 1: 20 (30) | |
| Cohort 2: 20 (30) | Cohort 2: 20 (30) | ||
| Cohort 3: 30 (40) | Cohort 3: 30 (40) | ||
| Patient Medical Expenses and Treatment Seeking Behavior | |||
| Percentage of patients with ADL seeking treatment per episode | 55 % (55–70 %) | 55 % (55–70 %) | [8, 11, 14, 44, 46] |
| India 70 % (70–98 %) | (India 75 % (75–98 %)) | ||
| Percentage of chronic disease patients seeking treatment | 20 % (20–50 %) | 30 % (30–55 %) | [9, 44, 45] |
| India: 50 % (41–80 %) | India 55 % (48–100 %) | ||
| Average patient medical expenses per ADL episode | +−20 % of baseline value | +−20 % of baseline value | [8, 11, 44–48] |
| Average patient medical expenses for chronic disease per year | +−20 % of baseline value | +−20 % of baseline value | [8, 11, 44–48] |
| Lost Productivity & Wages | |||
| Work days per year | 300 (261–365) days | 300 (261–365) days | |
| Percentage of work hours lost per day during an ADL episode | 75 % (50–93 %) | 75 % (50–93 %) | [12, 14, 16, 87] |
| Percentage of work hours lost due to chronic disease | 15 % (9–24 %) | 19 % (11–31 %) | [12, 43, 45, 46] |
| Discounting | |||
| Discount rate | 3 % (0–6 %) | 3 % (0–6 %) | [59] |
| Impact of Treatment | |||
| The reduction in transmission experienced by the treated population | Year 1: 50 % (35 %) | Year 1: 50 % (35 %) | [18] |
| Year 2: 75 % (53 %) | Year 2: 75 % (53 %) | ||
| Year 3: 88 % (62 %) | Year 3: 88 % (62 %) | ||
| Year 4: 94 % (66 %) | Year 4: 94 % (66 %) | ||
| Year 5 95 % (67 %) | Year 5 95 % (67 %) | ||
| Reduction in the frequency of ADL episodes by MDA | 50 % (15–88 %) | 50 % (15–88 %) | [33, 36, 37]. |
| Percentage of chronic disease alleviated by MDA | 10 % (0–90 %) | 15 % (0–69 %) | [20, 30–35] |
Based on [4], though updated where appropriate. ADL acute adenolymphangitis, MDA mass drug administration